Adiponectin and atherosclerosis

Czech version

Authors: D. Haluzíková ^1,2; T. Roubíček ¹; M. Haluzík ¹
Authors‘ workplace: III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA ¹; Ústav tělovýchovného lékařství 1. lékařské fakulty UK a VFN Praha, přednosta doc. MUDr. Zdeněk Vilikus, CSc. ²
Published in: Vnitř Lék 2007; 53(4): 359-363
Category: Reviews

Overview

Obesity combined with other components of the insulin resistance syndrome is an important risk factor for atherosclerosis and its complications. The exact mechanisms through which the above diseases are linked have not yet been fully elucidated. One of the possible links may be a disturbance of the endocrine function of the adipose tissue of obese persons which produces an increased amount of proinflammatory and proatherogenic hormones and a lower amount of factors protecting against such pathologies. Adiponectin is the only hormone produced by the adipose tissue with a proven antiinflammatory and antiatherosclerotic effect. This hormone is predominantly produced by adipocytes and its concentrations are decreased in patients with obesity, insulin resistance and atherosclerosis. The objective of the article is to summarize current experimental and clinical knowledge of the links between adiponectin and atherosclerosis and to discuss possible utilization of adiponectin as a marker for atherosclerosis, and the potential for its exploitation in the prevention and/or treatment of atherosclerosis.

Key words:
adiponectin – atherosclerosis – insulin resistance syndrome – obesity

Sources

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.

2. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286-288.

3. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.

4. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002; 13: 51-59.

5. Zhang Y, Proenca R, Maffei M et al.Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.

6. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830.

7. Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808.

8. Haffner SM Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract 2003; 61(Suppl 1): S9-S18.

9. Haluzik M, Parizkova J, Haluzik MM Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res 2004; 53: 123-129.

10. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.

11. Scherer PE, Williams S, Fogliano M et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-26749.

12. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-10703.

13. Nakano Y, Tobe T, Choi-Miura NH et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 1996; 120: 803-812.

14. Haluzik MM, Lacinova Z, Dolinkova M et al. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology 2006; 147: 4517-4524.

15. Haluzik M. diponectin and its potential in the treatment of obesity, diabetes and insulin resistance. Curr Opin Investig Drugs 2005; 6: 988-993.

16. Pajvani UB, Hawkins M, Combs TP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-12162.

17. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769.

18. Fasshauer M, Klein J, Neumann S et al. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290: 1084-1089.

19. Makimura H, Mizuno TM, Bergen H et al. Adiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with resistin mRNA. Am J Physiol Endocrinol Metab 2002; 283: E1266-E1271.

20. Puerta M, Abelenda M, Rocha M et al. Effect of acute cold exposure on the expression of the adiponectin, resistin and leptin genes in rat white and brown adipose tissues. Horm Metab Res 2002; 34: 629-634.

21. Housova J, Anderlova K, Krizova J et al. Serum adiponectin and resistin concentrations in patients with restrictive and binge/purge form of anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab 2005; 90: 1366-1370.

22. Schaffler A, Herfarth H, Paul G et al. Identification of influencing variables on adiponectin serum levels in diabetes mellitus type 1 and type 2. Exp Clin Endocrinol Diabetes 2004; 112: 383-389.

23. Matsuda M, Shimomura I, Sata M et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002; 277: 37487-37491.

24. Kubota N, Terauchi Y, Yamauchi T et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863-25866.

25. Kawanami D, Maemura K, Takeda N et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314: 415-419.

26. Ouchi N, Kihara S, Arita Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-1063.

27. Arita Y, Kihara S, Ouchi N et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893-2898.

28. Yamauchi T, Kamon J, Waki H et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-2468.

29. Okamoto Y, Kihara S, Ouchi N et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-2770.

30. Shibata R, Sato K, Pimentel DR et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 11: 1096-1103.

31. Shimabukuro M, Higa N, Asahi T et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003; 88: 3236-3240.

32. Jansson PA, Pellme F, Hammarstedt A et al. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. Faseb J 2003; 17: 1434-1440.

33. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.

34. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.

35. Hotta K, Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126-1133.

36. Kumada M, Kihara S, Sumitsuji S et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89.

37. Bahia L, Aguiar LG, Villela N et al. Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome. Atherosclerosis 2006; E-pub (v tisku).

38. Majuri A, Santaniemi M, Rautio K et al. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 2007; 156: 263-269.

39. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.